WO2003078583A3 - Optimization of crossover points for directed evolution - Google Patents

Optimization of crossover points for directed evolution Download PDF

Info

Publication number
WO2003078583A3
WO2003078583A3 PCT/US2003/007610 US0307610W WO03078583A3 WO 2003078583 A3 WO2003078583 A3 WO 2003078583A3 US 0307610 W US0307610 W US 0307610W WO 03078583 A3 WO03078583 A3 WO 03078583A3
Authority
WO
WIPO (PCT)
Prior art keywords
optimization
methods
directed evolution
crossover points
sequences
Prior art date
Application number
PCT/US2003/007610
Other languages
French (fr)
Other versions
WO2003078583A2 (en
Inventor
Sridhar Govindarajan
Claes Gustafsson
Jeremy S Minshull
Original Assignee
Maxygen Inc
Mundorff Emily C
Sridhar Govindarajan
Claes Gustafsson
Jeremy S Minshull
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc, Mundorff Emily C, Sridhar Govindarajan, Claes Gustafsson, Jeremy S Minshull filed Critical Maxygen Inc
Priority to JP2003576577A priority Critical patent/JP4851687B2/en
Priority to EP03711540A priority patent/EP1488335A4/en
Priority to AU2003213846A priority patent/AU2003213846A1/en
Publication of WO2003078583A2 publication Critical patent/WO2003078583A2/en
Publication of WO2003078583A3 publication Critical patent/WO2003078583A3/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/20—Screening of libraries
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment

Abstract

Methods and devices for more efficiently engineering diversity into recombinant polypeptides and/or nucleic acids are provided herein. For example, a variety of methods of selecting and/or assessing potential crossover sites in an amino acid sequence or a nucleotide sequence are provided, as well as the resulting chimeric product sequences. These methods include, e.g., consideration of structural, functional and/or statistical data in the selection and assessment of sequences and crossover sites for use in recombination.
PCT/US2003/007610 2002-03-09 2003-03-10 Optimization of crossover points for directed evolution WO2003078583A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003576577A JP4851687B2 (en) 2002-03-09 2003-03-10 Crossover optimization for directed evolution
EP03711540A EP1488335A4 (en) 2002-03-09 2003-03-10 Optimization of crossover points for directed evolution
AU2003213846A AU2003213846A1 (en) 2002-03-09 2003-03-10 Optimization of crossover points for directed evolution

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36350502P 2002-03-09 2002-03-09
US60/363,505 2002-03-09
US37359102P 2002-04-18 2002-04-18
US60/373,591 2002-04-18

Publications (2)

Publication Number Publication Date
WO2003078583A2 WO2003078583A2 (en) 2003-09-25
WO2003078583A3 true WO2003078583A3 (en) 2004-03-18

Family

ID=28045308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007610 WO2003078583A2 (en) 2002-03-09 2003-03-10 Optimization of crossover points for directed evolution

Country Status (5)

Country Link
US (3) US7620500B2 (en)
EP (1) EP1488335A4 (en)
JP (3) JP4851687B2 (en)
AU (1) AU2003213846A1 (en)
WO (1) WO2003078583A2 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078583A2 (en) 2002-03-09 2003-09-25 Maxygen, Inc. Optimization of crossover points for directed evolution
US9322027B2 (en) 2010-08-20 2016-04-26 Shell Oil Company Expression constructs comprising fungal promoters
CN103080306B (en) 2010-08-20 2015-02-18 科德克希思公司 Use of glycoside hydrolase 61 family proteins in processing of cellulose
US8663962B2 (en) 2011-03-30 2014-03-04 Codexis, Inc. Pentose fermentation by a recombinant microorganism
BR112013033614A2 (en) 2011-06-30 2018-05-29 Codexis Inc pentose fermentation by recombinant microorganism
DK2748317T3 (en) 2011-08-22 2017-07-17 Codexis Inc GH61 glycoside hydrolase protein variants and cofactors that enhance GH61 activity
US20130084608A1 (en) 2011-09-30 2013-04-04 Codexis, Inc. Fungal proteases
EP2794871A4 (en) 2011-12-20 2015-12-30 Codexis Inc Endoglucanase 1b (eg1b) variants
JP6542662B2 (en) * 2012-03-20 2019-07-10 サレプタ セラピューティクス， インコーポレイテッド Boronic acid conjugates of oligonucleotide analogs
WO2013188305A2 (en) 2012-06-11 2013-12-19 Codexis, Inc. Fungal beta-xylosidase variants
CA2891482A1 (en) 2012-11-20 2014-05-30 Codexis, Inc. Pentose fermentation by a recombinant microorganism
MY193198A (en) 2013-04-18 2022-09-26 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
EP3049973B1 (en) 2013-09-27 2018-08-08 Codexis, Inc. Automated screening of enzyme variants
CN106232619B (en) 2013-11-13 2022-09-09 科德克希思公司 Engineered imine reductases and methods for reductive amination of ketone and amine compounds
HUE056444T2 (en) 2014-04-16 2022-02-28 Codexis Inc Engineered tyrosine ammonia lyase
EP3167052B1 (en) 2014-07-09 2020-01-01 Codexis, Inc. P450-bm3 variants with improved activity
WO2016085916A1 (en) 2014-11-25 2016-06-02 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
KR102438885B1 (en) 2014-12-22 2022-09-01 코덱시스, 인코포레이티드 Human alpha-galactosidase variants
US10696953B2 (en) 2015-02-10 2020-06-30 Codexis, Inc. Ketoreductase polypeptides for the synthesis of chiral compounds
WO2016179464A1 (en) 2015-05-07 2016-11-10 Codexis, Inc. Penicillin-g acylases
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
DK3319987T3 (en) 2015-07-07 2021-06-21 Codexis Inc NEW P450-BM3 VARIANTS WITH IMPROVED ACTIVITY
DK3452587T3 (en) 2016-05-05 2021-10-11 Codexis Inc PENICILLIN-G-ACYLASER
CN109715817B (en) 2016-06-09 2022-12-09 科德克希思公司 Biocatalysts and methods for hydroxylation of chemical compounds
WO2017218325A1 (en) 2016-06-15 2017-12-21 Codexis, Inc. Engineered beta-glucosidases and glucosylation methods
CA3032519A1 (en) 2016-08-26 2018-03-01 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
US10745681B2 (en) 2017-01-05 2020-08-18 Codexis, Inc. Penicillin-G acylases
EP3577229A4 (en) 2017-02-03 2020-12-23 Codexis, Inc. Engineered glycosyltransferases and steviol glycoside glucosylation methods
BR112019016634A2 (en) 2017-02-13 2020-04-07 Codexis Inc polypeptides, engineered polynucleotide sequence, expression vector, host cell, methods for producing an engineered phenylalanine ammonia lyase polypeptide in a host cell and for treating and / or preventing phenylketonuria symptoms in an individual, composition, and , use
CN117511890A (en) 2017-04-27 2024-02-06 科德克希思公司 Ketoreductase polypeptides and polynucleotides
SG11201909957TA (en) 2017-05-08 2019-11-28 Codexis Inc Engineered ligase variants
CN111032682B (en) 2017-06-14 2024-04-12 科德克希思公司 Engineered transaminase polypeptides for industrial biocatalysis
CN117737045A (en) 2017-06-27 2024-03-22 科德克希思公司 Penicillin G acylase
KR20200023454A (en) 2017-06-30 2020-03-04 코덱시스, 인코포레이티드 T7 RNA Polymerase Variants
US10793841B2 (en) 2017-06-30 2020-10-06 Codexis, Inc. T7 RNA polymerase variants
CN111511389A (en) 2017-11-07 2020-08-07 科德克希思公司 Transglutaminase variants
US11015180B2 (en) 2017-12-13 2021-05-25 Codexis, Inc. Carboxyesterase polypeptides for amide coupling
WO2019241132A1 (en) 2018-06-12 2019-12-19 Codexis, Inc. Engineered tyrosine ammonia lyase
US11274286B2 (en) 2018-07-09 2022-03-15 Codexis, Inc. Engineered deoxyribose-phosphate aldolases
AU2019300838A1 (en) 2018-07-09 2021-01-07 Codexis, Inc. Engineered pantothenate kinase variant enzymes
SG11202012138XA (en) 2018-07-09 2021-01-28 Codexis Inc Engineered galactose oxidase variant enzymes
CN112601821A (en) 2018-07-09 2021-04-02 科德克希思公司 Engineered pentose phosphate mutase variant enzymes
US11162105B2 (en) 2018-07-09 2021-11-02 Codexis, Inc. Engineered purine nucleoside phosphorylase variant enzymes
US11198861B2 (en) 2018-07-12 2021-12-14 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
US11760981B2 (en) 2018-07-30 2023-09-19 Codexis, Inc. Engineered glycosyltransferases and steviol glycoside glucosylation methods
BR112021008186A2 (en) 2018-10-29 2021-08-17 Codexis, Inc. engineered dna polymerase, polynucleotide sequence, expression vector, host cell, composition, high-throughput assay system, and, methods for producing a engineered dna polymerase polypeptide in a host cell and for determining high throughput fidelity of a dna polymerase.
SG11202105668PA (en) 2018-12-14 2021-06-29 Codexis Inc Engineered tyrosine ammonia lyase
EP3898960A4 (en) 2018-12-20 2022-11-30 Codexis, Inc. Human alpha-galactosidase variants
US11788071B2 (en) 2020-04-10 2023-10-17 Codexis, Inc. Engineered transaminase polypeptides
US11959108B2 (en) 2020-08-28 2024-04-16 Codexis, Inc. Engineered protease variants
BR112023003643A2 (en) 2020-08-28 2023-03-28 Codexis Inc RECOMBINANT AMYLASE, COMPOSITION, RECOMBINANT POLYNUCLEOTIDE SEQUENCE, EXPRESSION VECTOR, HOST CELL, METHODS FOR PRODUCING A RECOMBINANT AMYLASE AND FOR TREAT AND/OR PREVENT THE SYMPTOMS OF PANCREATIC FAILURE, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PANCREATIC FAILURE, AND, USE
WO2022133289A2 (en) 2020-12-18 2022-06-23 Codexis, Inc. Engineered uridine phosphorylase variant enzymes
CA3214972A1 (en) 2021-04-02 2022-10-06 Codexis, Inc. Engineered adenylate kinase variant enzymes
CA3214975A1 (en) 2021-04-02 2022-10-06 Codexis, Inc. Engineered cyclic gmp-amp synthase (cgas) variant enzymes
US20220325284A1 (en) 2021-04-02 2022-10-13 Codexis, Inc. Engineered guanylate kinase variant enzymes
CN117222735A (en) 2021-04-02 2023-12-12 科德克希思公司 Engineered acetate kinase variant enzymes
WO2024040020A1 (en) 2022-08-15 2024-02-22 Absci Corporation Quantitative affinity activity specific cell enrichment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075767A2 (en) * 2000-03-30 2001-10-11 Maxygen, Inc. In silico cross-over site selection

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US5741691A (en) 1996-01-23 1998-04-21 California Institute Of Technology Para-nitrobenzyl esterases with enhanced activity in aqueous and nonaqueous media
KR20000064670A (en) 1996-03-19 2000-11-06 부르너 데이빗 Kinases capable of site-specific phosphorylation of IκＢα
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
IL130635A0 (en) 1997-01-17 2000-06-01 Maxygen Inc Evolution of whole cells and organisms by recursive sequence recombination
CA2284253A1 (en) 1997-03-18 1998-09-24 Jesper Vind An in vitro method for construction of a dna library
DE69840382D1 (en) 1997-03-18 2009-02-05 Novozymes As METHOD FOR THE PRODUCTION OF A LIBRARY THROUGH DNA SHUFFLING
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6153410A (en) 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
AU1124499A (en) 1997-10-28 1999-05-17 Maxygen, Inc. Human papillomavirus vectors
EP1030861A4 (en) 1997-10-31 2001-09-05 Maxygen Inc Modification of virus tropism and host range by viral genome shuffling
AU746786B2 (en) 1997-12-08 2002-05-02 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
AU3289199A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Antigen library immunization
JP2002503478A (en) 1998-02-11 2002-02-05 マキシジェン， インコーポレイテッド Targeting gene vaccine vectors
US6109776A (en) 1998-04-21 2000-08-29 Gene Logic, Inc. Method and system for computationally identifying clusters within a set of sequences
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
JP4700805B2 (en) 1998-06-29 2011-06-15 ブリストル−マイヤーズ スクウィブ カンパニー How to make a highly diverse library
FR2782323B1 (en) 1998-08-12 2002-01-11 Proteus PROCESS FOR THE IN VITRO PRODUCTION OF RECOMBINANT POLYNUCLEOTIDE SEQUENCES, SEQUENCE BANKS AND SEQUENCES THUS OBTAINED
EP1117777A2 (en) 1998-09-29 2001-07-25 Maxygen, Inc. Shuffling of codon altered genes
JP2002526107A (en) 1998-10-07 2002-08-20 マキシジェン， インコーポレイテッド DNA shuffling to generate nucleic acids for mycotoxin detoxification
WO2000042559A1 (en) 1999-01-18 2000-07-20 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
EP1108783A3 (en) 1999-01-19 2001-09-05 Maxygen, Inc. Oligonucleotide-mediated nucleic acid recombination
AU1098001A (en) 1999-10-19 2001-04-30 Enchira Biotechnology Corporation Method for directed evolution by random chimeragenesis on transient templates
WO2001029212A1 (en) 1999-10-19 2001-04-26 Enchira Biotechnology Corporation Methods for chimeragenesis of whole genomes or large polynucleotides
US20030032059A1 (en) 2000-05-23 2003-02-13 Zhen-Gang Wang Gene recombination and hybrid protein development
AU2001263411A1 (en) 2000-05-23 2001-12-03 California Institute Of Technology Gene recombination and hybrid protein development
WO2003078583A2 (en) 2002-03-09 2003-09-25 Maxygen, Inc. Optimization of crossover points for directed evolution

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075767A2 (en) * 2000-03-30 2001-10-11 Maxygen, Inc. In silico cross-over site selection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEMMER W.P.C.: "Rapid evolution of a protein in vitro by DNA shuffling", NATURE, vol. 370, 4 August 1994 (1994-08-04), pages 389 - 391, XP002912216 *

Also Published As

Publication number Publication date
US7620500B2 (en) 2009-11-17
US8224580B2 (en) 2012-07-17
WO2003078583A2 (en) 2003-09-25
US20030198988A1 (en) 2003-10-23
EP1488335A2 (en) 2004-12-22
JP2011217751A (en) 2011-11-04
AU2003213846A1 (en) 2003-09-29
US20100070192A1 (en) 2010-03-18
JP4851687B2 (en) 2012-01-11
JP2005520244A (en) 2005-07-07
AU2003213846A8 (en) 2003-09-29
US8108150B2 (en) 2012-01-31
JP2010015581A (en) 2010-01-21
EP1488335A4 (en) 2006-11-15
US20080020397A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
WO2003078583A3 (en) Optimization of crossover points for directed evolution
WO2000060060A3 (en) Polypeptides having alkaline alpha-amylase activity and nucleic acids encoding same
WO2005074656A3 (en) Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
WO2005001064A3 (en) Polypeptides having alpha-amylase activity and polypeptides encoding same
WO2004101760A3 (en) Novel lipolytic enzyme elip
ATE342917T1 (en) ANTIMICROBIAL POLYPEPTIDES FROM PSEUDOPLECTANIA NIGRELLA
WO2006078256A3 (en) Polypeptides having xylanase activity and polynucleotides encoding same
DE69635444D1 (en) CLEANED COPRINUS LACCASES AND NUCLEIC ACIDS THAT CODE FOR THIS
WO2004101759A3 (en) Novel lipolytic enzyme lip2
WO2000060058A3 (en) Polypeptides having alkaline alpha-amylase activity and nucleic acids encoding same
WO2003052055A3 (en) Egvii endoglucanase and nucleic acids encoding the same
HK1071375A1 (en) Egviii endoglucanase and nucleic acids encoding the same egviii
WO2001079463A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
MX282672B (en) Proteases, nucleic acids encoding them and methods for making and using them.
WO2003052118A3 (en) Bgl4 beta-glucosidase and nucleic acids encoding the same
EP1108781A3 (en) Method for making character strings, polynucleotides and polypeptides
WO2004080148A3 (en) Novel nucleic acids and polypeptides
DE69840230D1 (en) POLYPEPTIDES WITH PROLYLDIPEPTIDYLAMINOPEPTIDASE ACTIVITY AND NUCLEIC ACIDS THAT CODE FOR IT
WO2003078645A3 (en) Methods for generating double stranded dna comprising a 3’ single stranded portion and uses of these complexes for recombination
WO2003089598A3 (en) Polypeptides having xyloglucanase activity and nucleic acids encoding same
DK1165759T3 (en) Polypeptides that have branching enzyme activity and nucleic acids encoding the same
WO2006053021A3 (en) Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby
NO20072966L (en) Polypeptides having antimicrobial activity and polynucleotides encoding them
DK0981631T3 (en) Polypeptides having aminopeptidase activity and nucleic acids encoding the same
WO2006005032A3 (en) Polypeptides having alpha-glucosidase activity and polynucleotides encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003576577

Country of ref document: JP

REEP Request for entry into the european phase

Ref document number: 2003711540

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003711540

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003711540

Country of ref document: EP